Literature DB >> 33086320

A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak.

Jashodeep Datta1, Gregory C Wilson2, Michael I D'Angelica3, Matthew H G Katz4, Shishir K Maithel5, Nipun B Merchant1, Syed A Ahmad2.   

Abstract

Entities:  

Year:  2021        PMID： 33086320     DOI： 10.1097/SLA.0000000000004471

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  4 in total

1.  Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma.

Authors:  Omar Abdel-Rahman; Jennifer Spratlin; Sheryl Koski
Journal:  Med Oncol       Date:  2021-02-03       Impact factor: 3.064

2.  Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response.

Authors:  Dany Barrak; Anthony M Villano; Nicole Villafane-Ferriol; Leah G Stockton; Maureen V Hill; Mengying Deng; Elizabeth A Handorf; Sanjay S Reddy
Journal:  Eur J Surg Oncol       Date:  2022-01-05       Impact factor: 4.037

Review 3.  The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer.

Authors:  Argyrios Gyftopoulos; Ioannis A Ziogas; Andrew S Barbas; Dimitrios Moris
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

4.  Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement.

Authors:  Joshua S Jolissaint; Marsha Reyngold; Jared Bassmann; Kenneth P Seier; Mithat Gönen; Anna M Varghese; Kenneth H Yu; Wungki Park; Eileen M O'Reilly; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; T Peter Kingham; Kevin C Soares; William R Jarnagin; Christopher H Crane; Alice C Wei
Journal:  Ann Surg       Date:  2021-12-01       Impact factor: 13.787
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.